Immuneering Corp (IMRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $240.27M
Last updated: Nov 17, 2026 at 11:05 AM ET
Immuneering Corp (IMRX) Stock Forecast
Analysts expect Immuneering (IMRX) to earn -$1.26 per share in the fiscal year ending Dec 31, 2026. Of 7 analysts, 7 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 1.71, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 28.6% |
| Buy | 5 | 71.4% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 7
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$1.26
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$1.64
- EPS consensus
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$1.26 | -$1.30 to -$1.23 | 7 |
| Dec 31, 2027 | -$1.64 | -$1.87 to -$1.38 | 7 |
Quarterly Estimates
The EPS consensus falls from -$0.35 for the quarter ending Dec 31, 2026 to -$0.40 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.35 | -$0.44 to -$0.30 | 9 |
| Mar 31, 2027 | -$0.40 | -$0.41 to -$0.38 | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 5 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 2 |
| Fiscal year ending Dec 31, 2027 | 0 | 2 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.14.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.26 | -$1.26 | -$1.12 | -$1.12 | -$1.14 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.64 | -$1.61 | -$1.26 | -$1.26 | -$1.29 | N/A |
| Quarter ending Mar 31, 2027 | -$0.40 | -$0.37 | -$0.34 | -$0.34 | -$0.33 | N/A |
Frequently Asked Questions About IMRX
What is the IMRX stock forecast?
Consensus analyst estimates put Immuneering's EPS at -$1.26 for the fiscal year ending Dec 31, 2026. The consensus rating from 7 analysts is Buy.
How do analysts rate IMRX stock?
Of 7 analysts covering Immuneering, 2 rate it Strong Buy, 5 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from IMRX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.26, with estimates from -$1.30 to -$1.23 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.64, with estimates from -$1.87 to -$1.38 from 7 analysts.
How many analysts cover IMRX?
7 analysts rate Immuneering stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
IMRX pages: Overview, Earnings, Forecast, Financials, Competitors